Penn Medicine’s campus in Philadelphia; the study’s senior author is on the faculty of Penn’s Perelman School of Medicine. Photo: ajay_suresh, CC BY 2.0, via Wikimedia Commons.
A genetic study drawing on more than 1 million people has found 58 regions of the genome linked to endometriosis, 27 of them never identified before, in what the National Institutes of Health calls one of the largest looks yet at why the disease develops.
The work, announced by NIH on Nov. 20 and published in Nature Genetics, pooled data from 14 biobanks around the world. More than 30% of the participants were of non-European ancestry, a deliberate break from earlier genetic studies of the condition that relied mostly on people of European descent, with smaller East Asian samples.
Endometriosis, in which tissue similar to the lining of the uterus grows elsewhere in the body, affects up to 1 in 10 women worldwide, according to NIH. It can lead to severe pain and fertility problems, and NIH notes it may be associated with risk for other diseases. There is no cure yet.
What the researchers found
The team ran a meta-analysis across the biobanks, then layered on what scientists call multi-omic analysis, which combines several types of biological data to see which genes are actually doing something in the disease. Beyond the 58 genomic regions, the study:
- Identified 314 genes that may be associated with endometriosis.
- Found that endometriosis shares genetic links with 135 other health conditions or traits.
- Turned up associations that had not been seen before by including people of African ancestry and Admixed-American ancestry, meaning mixed North, Central and South American heritage.
That last point is the one most likely to matter to patients over time. Genetic findings drawn from a narrow population can miss risk factors common in other groups, which then shapes who gets studied, screened and treated. Widening the sample is how researchers start to close that gap.
“By studying many types of biological data across people with different ancestries, we were able to increase our understanding of how endometriosis develops and affects the body,” said Shefali Setia-Verma, Ph.D., the study’s senior author and an assistant professor of pathology and laboratory medicine at the University of Pennsylvania Perelman School of Medicine. She said the findings should guide research toward “better diagnosis, personalized risk assessment, and treatments that target the disease.”
Why a gene map doesn’t mean a new drug yet
Studies like this one point to biology, not prescriptions. A region of the genome linked to a disease is a lead that labs then have to chase: which gene in that region matters, what it does, and whether changing its activity helps. NIH framed the results the same way, saying they “could someday lead to studies on potential targets for therapeutic interventions.”
The overlap with 135 other conditions is also a lead rather than a conclusion. Shared genetics can help explain why some patients with endometriosis also deal with other illnesses, and it can point researchers toward drugs already approved for related conditions. It does not mean one condition causes another.
“The findings from this large multi-ancestry study provide a wealth of information on the genetic underpinnings of endometriosis, a severely painful condition for which NIH is actively pursuing a cure,” said John Gaitanis, M.D., director of NIH’s Eunice Kennedy Shriver National Institute of Child Health and Human Development, which supported the study.
The study adds to a busy stretch of women’s health and rare-disease news. In recent weeks the FDA approved Wilserdly for ESR1-mutated advanced breast cancer and Livsayis for generalized myasthenia gravis. Our health coverage tracks those approvals as they come.
The paper itself, “Multi-ancestry genome-wide association and integrative multi-omics analyses implicate key pathways in endometriosis” by Guare and colleagues, is available through Nature Genetics. The next step is in the lab, where researchers will test which of the 314 genes are worth building treatments around.
Add Verity News as a preferred source on Google (opens in a new tab)